Evidence map›Paper›PMID 24623969›Full record

ArticleMolecular vision2014

Gene regulation by PAX6: structural-functional correlations of missense mutants and transcriptional control of Trpm3/miR-204.

Qing Xie, Devina Ung, Kamil Khafizov, Andras Fiser, Ales Cvekl

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. TRPM3 in Brain (Patho)Physiology.Frontiers in cell and developmental biology · 2021
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Molecular vision · 2018
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Qing XieDepartment of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine, Bronx, NY.
Devina UngDepartment of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine, Bronx, NY.
Kamil KhafizovDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY ; Department of Systems and Computational Biology, Albert Einstein College of Medicine, Bronx, NY.
Andras FiserDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY ; Department of Systems and Computational Biology, Albert Einstein College of Medicine, Bronx, NY.
Ales CveklDepartment of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine, Bronx, NY ; Department of Genetics, Albert Einstein College of Medicine, Bronx, NY.
Albert Einstein College of Medicine · US

Funding

PAX-6 AS A KEY REGULATOR OF LENS DEVELOPMENTR01EY012200 · NEI · YESHIVA UNIVERSITY · PI CVEKL, ALES · 2000 to 2025
$13.1M
NEI NIH HHS R01 EY012200NEI NIH HHS R01EY012200
6 · The paper itself

Abstract

purposePax6 is a key regulatory gene for eye, brain, and pancreas development. It acts as a transcriptional activator and repressor. Loss-of-function of Pax6 results in down- and upregulation of a comparable number of genes, although many are secondary targets. Recently, we found a prototype of a Pax6-binding site that acts as a transcriptional repressor. We also identified the Trpm3 gene as a Pax6-direct target containing the miR-204 gene located in intron 6. Thus, there are multiple Pax6-dependent mechanisms of transcriptional repression in the cell. More than 50 Pax6 missense mutations have been identified in humans and mice. Two of these mutations, N50K (Leca4) and R128C (Leca2), were analyzed in depth resulting in different numbers of regulated genes and different ratios of down- and upregulated targets. Thus, additional studies of these mutants are warranted to better understand the molecular mechanisms of the mutants' action.

methodsMutations in PAX6 and PAX6(5a), including G18W, R26G, N50K, G64V, R128C, and R242T, were generated with site-directed mutagenesis. A panel of ten luciferase reporters driven by six copies of Pax6-binding sites representing a spectrum of sites that act as repressors, moderate activators, and strong activators were used. Two additional reporters, including the Pax6-regulated enhancer from mouse Trpm3 and six copies of its individual Pax6-binding site, were also tested in P19 cells.

resultsPAX6 (N50K) acted either as a loss-of-function or neutral mutation. In contrast, PAX6 (R128C) and (R242T) acted as loss-, neutral, and gain-of-function mutations. With three distinct reporters, the PAX6 (N50K) mutation broke the pattern of effects produced by substitutions in the surrounding helices of the N-terminal region of the paired domain. All six mutations tested acted as loss-of-function using the Trpm3 Pax6-binding site.

conclusionsThese studies highlight the complexity of Pax6-dependent transcriptional activation and repression mechanisms, and identify the N50K and R128C substitutions as valuable tools for testing interactions between Pax6, Pax6 (N50K), and Pax6 (R128C) with other regulatory proteins, including chromatin remodelers.

Indexed as

Gene Expression RegulationTranscription, GeneticAnimalsBase SequenceEye ProteinsGenes, ReporterHomeodomain ProteinsHumansLuciferasesMiceMicroRNAsMolecular Sequence DataMutation, MissenseNucleotide MotifsPaired Box Transcription FactorsPAX6 Transcription FactorEye ProteinsHomeodomain ProteinsLuciferasesMicroRNAsMIRN204 microRNA, mousePaired Box Transcription FactorsPAX6 protein, humanPax6 protein, mousePAX6 Transcription FactorRepressor ProteinsTRPM3 protein, mouseTRPM Cation Channels

Identifiers

PMID24623969
PMCPMC3945805
OpenAlexW2117752976

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.